Addiction Medicine and Addiction Psychiatry Updates

 Access all these at  https://pcssnow.org/mentoring/clinical-roundtable/archived-clinical-roundtables/ Ready or Not Here Come Xylazine and the Nitazenes – June 6, 2023 Harm Reduction: Practical Application in the Clinical Setting for Healthcare Professionals – May 18, 2023 Helping Dental Professionals Identify and Support Patients with Substance Use Disorders – May 12, 2023 Xylazine and How it Harms People Who Use Drugs – April 11, 2023 Rethinking the Role of the Family in Addiction Care – April 3, 2023 Comparing Methods of Buprenorphine Induction in Patients Using Fentanyl – January 6, 2023 Fentanyl and Opioid Use Disorder – December 1, 2022 When to Terminate Buprenorphine Maintenance – November 8, 2022 Opioid Use Disorder in Pregnancy – October 27, 2022 Stigma Kills: Addressing Substance Use Disorder by Changing Culture – October 14, 2022

https://www.addictionpolicy.org/post/new-study-on-stigmatizing-imagery-for-substance-use-disorders-released https://www.biomedcentral.com/epdf/10.1186/s40352-023-00229-6

  Overdose deaths involving illicitly manufactured fentanyl where the veterinary tranquilizer xylazine (“tranq”) was also detected jumped 276% from January 2019 through June 2022, a   study   in   Morbidity and Mortality Weekly Report   has found. https://alert.psychnews.org/2023/07/xylazine-present-in-increasing-number.html

 https://www.acpjournals.org/doi/10.7326/M23-0053  This study did not identify important effects of medical cannabis laws on receipt of opioid or nonopioid pain treatment among patients with chronic noncancer pain. https://doi.org/10.7326/M23-0053